Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26845500 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL31503047 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL26845492 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL26845493 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40248 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL19228951 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL193907 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40286 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL9511 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL40247 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024231837-A1 | NEW BORON-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITA' DEGLI STUDI DI TORINO (IT) | 2024-11-14 | — | — | WO | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025233682-A1 | ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS AND USES THEREOF | LIGACHEM BIOSCIENCES INC. (KR) | 2025-11-13 | — | — | WO | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250236633-A1 | SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES | Roche Sequencing Solutions, Inc. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2025-04-24 | — | — | US | disclosed |
| US-20110250353-A1 | Process for the preparation of a cross-linked multilayer film | THE UNIVERSITY OF MELBOURNE (AU) | 2011-10-13 | — | — | US | disclosed |
| US-20110250353-A1 | Process for the preparation of a cross-linked multilayer film | THE UNIVERSITY OF MELBOURNE (AU) | 2011-10-13 | — | — | US | disclosed |
| US-20110224383-A1 | POLY(ETHYLENE GLYCOL) DERIVATIVES FOR METAL-FREE CLICK CHEMISTRY | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7947328-B2 | Metal pattern forming method | FUJIFILM CORPORATION (JP) | 2011-05-24 | — | — | US | disclosed |
| US-7893277-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100280252-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100160645-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-7560588-B2 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090087570-A1 | METAL PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | INTEZYNE TECHNOLOGIES (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280252-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | GNE, EPRS1, ALG1 | MEN1 2092/4885KMT2A 3924/4885TSHR 3867/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885TSHR 3319/4885 |
| US-20100160645-A1 | POLY(ETHYLENE GLYCOL) CONTAINING CHEMICALLY DISPARATE ENDGROUPS | GNE, EPRS1, ALG1 | MEN1 2092/4885KMT2A 3924/4885TSHR 3867/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885TSHR 3319/4885 |
| US-20250288573-A1 | DIMERIC IMMUNO-MODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS | CRBN, CD4, CDR2 | MEN1 2337/4885KMT2A 3266/4885TSHR 4105/4885 |
| US-20250129082-A1 | N-1 Triazole Substituted Imidazoquinolines, Conjugates Thereof, and Methods | IFNG, IFNAR1, IL2 | MEN1 707/4885KMT2A 2358/4885TSHR 1515/4885 |
| US-20250236633-A1 | SYNTHESIS OF ISOMERICALLY PURE POLYOL-BASED PHOSPHORAMIDITES | PARG, PPA1, PGM2 | MEN1 947/4885KMT2A 1439/4885TSHR 4736/4885 |
| US-20080207913-A1 | Poly(ethylene glycol) containing chemically disparate endgroups | GNE, EPRS1, ALG1 | MEN1 2092/4885KMT2A 3924/4885TSHR 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.